State Street Holds 5.1% Of Biogen With A Smaller Voting Position

The reported holding covered 7,570,589 shares, with shared voting authority over 4,863,692.

Share
State Street Holds 5.1% Of Biogen With A Smaller Voting Position

State Street reported a 5.1% stake in Biogen, which develops and sells treatments for serious diseases, but its voting authority covered fewer shares than its ownership position. The passive ownership disclosure filed Tuesday put the holding at 7,570,589 common shares as of September 30, 2026.

Ownership Exceeds Voting Authority

State Street had shared voting authority over 4,863,692 shares. It also shared authority to sell or otherwise dispose of 7,562,236 shares, with neither voting nor disposal authority held solely by State Street.

The 5.1% figure measures beneficial ownership of Biogen's common-stock class; it does not mean State Street can vote that entire position. State Street certified that the securities were bought and held as part of its ordinary business, rather than for changing or influencing Biogen's control.

Lupus Results In The Backdrop

Biogen's business centers on neurology, specialized immunology and rare diseases. Its treatments span multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia and ALS; it also works with Eisai on LEQEMBI for Alzheimer's disease and Supernus on ZURZUVAE for postpartum depression.

TYSABRI and SPINRAZA each accounted for more than 10.0% of Biogen's total revenue in 2025, 2024 and 2023. Biogen's market value was $37.7 billion as of 7:19 a.m. ET Tuesday.

On Monday, Biogen and UCB published additional lupus analysis from their late-stage trial, which met its main goal. The analysis examined improvement across organ domains affected by the disease.

Through week 48, about 61% of patients given dapirolizumab pegol plus standard care improved in at least half of those domains. The corresponding figure was about 43% for patients given placebo plus standard care.

The lupus analysis was conducted after the trial, and its authors said the response measure needs further validation.

Sources

More on Biogen

All Biogen (BIIB) coverage →